Accéder au contenu
Merck
Toutes les photos(2)

Documents

MKI2MAG-94K

Millipore

MILLIPLEX® Mouse Kidney Injury Magnetic Bead Panel 2 - Toxicity Multiplex Assay

The analytes available for this multiplex kit are: Clusterin, Cystatin C, EGF, Lipocalin-2/NGAL, Osteopontin (OPN) (for urine samples) or Clusterin, Cystatin C, Lipocalin-2/NGAL, Osteopontin (OPN) (for serum/plasma samples).

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(2)

About This Item

Code UNSPSC :
12161503
eCl@ss :
32161000
Nomenclature NACRES :
NA.84

Niveau de qualité

200

Espèces réactives

mouse

Fabricant/nom de marque

Milliplex®

assay range

accuracy: 90-99%
sensitivity: 0.005-0.190 ng/mL
(MinDC+2SD)
standard curve range: 0.005-5 ng/mL
(Lipocalin-2/NGAL)
standard curve range: 0.01-10 ng/mL
(Osteopontin (OPN))
standard curve range: 0.04-40 ng/mL
(EGF)
standard curve range: 0.05-50 ng/mL
(Cystatin C)
standard curve range: 0.2-250 ng/mL
(Clusterin)

Technique(s)

multiplexing: suitable

Méthode de détection

fluorometric (Luminex xMAP)

Conditions d'expédition

wet ice

Catégories apparentées

Description générale

Maintenance of physiological balance in the body is attributed in part to normal kidney function. An altered kidney function due to injury, drug toxicity or kidney failure may be life threatening. There are multiple risk factors for kidney injury including age, hypertension, diabetes mellitus, heart failure and liver failure. On the other hand, drug induced damage to the kidney results from drug excretion. Traditional markers for assessing renal toxicity, such as blood urea nitrogen (BUN) and serum creatinine, are insensitive and non-specific. Although both are direct measurements of renal function, increases in serum concentrations of these biomarkers occur only after substantial renal injury. Specificity and earlier detection of kidney injury is vital. For improved detection of acute nephrotoxicity, a panel of novel urinary kidney biomarkers has been identified and validated for preclinical studies in relevant animal species. We provide valuable research assays to investigate multiple biomarkers of kidney injury in mouse urine samples using the Luminex® xMAP® instrument platform.

The MILLIPLEX® Mouse Kidney Injury Bead Panel 2 contains all the components necessary to measure the following five biomarkers in any combination using Luminex® xMAP® technology: Clusterin, Cystatin C, EGF, Lipocalin-2/NGAL, Osteopontin (OPN). The kit uses a 96-well format, contains a lyophilized standard cocktail, two quality controls and can measure up to 38 urine samples in duplicate.

Panel Type: Toxicity

Spécificité

There was no or negligible cross-reactivity between the antibodies for an analyte and any of the other analytes within a panel.

Application

  • Analytes: Clusterin, Cystatin C, EGF, Lipocalin-2/NGAL, Osteopontin (OPN)
  • Recommended Sample type: urine
  • Recommended Sample dilution: 1:1,000
  • Assay Run Time: overnight
  • Research Category: Toxicity

Caractéristiques et avantages

Design your multiplex kit by choosing available analytes within this panel.

Conditionnement

Everything you need in a single kit.

Stockage et stabilité

Recommended storage for kit components is 2 - 8°C.

Autres remarques

Please contact Technical Service for linearity of dilution.
Sensitivity: Please see kit protocol for individual assay sensitivities.

Informations légales

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Clause de non-responsabilité

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Mention d'avertissement

Danger

Classification des risques

Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

Organes cibles

Respiratory Tract

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Karima Relizani et al.
Nucleic acids research, 50(1), 17-34 (2021-12-12)
Tricyclo-DNA (tcDNA) is a conformationally constrained oligonucleotide analog that has demonstrated great therapeutic potential as antisense oligonucleotide (ASO) for several diseases. Like most ASOs in clinical development, tcDNA were modified with phosphorothioate (PS) backbone for therapeutic purposes in order to
Lucía Echevarría et al.
Methods in molecular biology (Clifton, N.J.), 2434, 371-384 (2022-02-26)
Antisense oligonucleotides (ASO) therapeutics hold great promise for the treatment of numerous diseases, and several ASO drugs have now reached market approval, confirming the potential of this approach. However, some candidates have also failed, due to limited biodistribution/uptake and poor
Karima Relizani et al.
Molecular therapy. Nucleic acids, 8, 144-157 (2017-09-18)
Antisense oligonucleotides (AONs) hold promise for therapeutic splice-switching correction in many genetic diseases. However, despite advances in AON chemistry and design, systemic use of AONs is limited due to poor tissue uptake and sufficient therapeutic efficacy is still difficult to
Philippine Aupy et al.
Molecular therapy. Nucleic acids, 19, 371-383 (2019-12-28)
Tricyclo-DNA (tcDNA) antisense oligonucleotides (ASOs) hold promise for therapeutic splice-switching applications and the treatment of Duchenne muscular dystrophy (DMD) in particular. We have previously reported the therapeutic potential of tcDNA-ASO in mouse models of DMD, highlighting their unique pharmaceutical properties

Contenu apparenté

Kidney Toxicity Multiplex Assays | MILLIPLEX®

Multiplex kidney toxicity assays detect nephrotoxicity biomarkers in small samples, minimizing time and costs for toxicity screening.

Multiplex Toxicity Assays

MILLIPLEX® toxicity assays advance liver, kidney, and genotoxicity research by simultaneously measuring multiple toxicity biomarkers.

Overview of Luminex® Multiplex Assay Technology | MILLIPLEX® Multiplex Assays

Discover the benefits of MILLIPLEX® multiplex assays, based on Luminex® xMAP® multiplex assay technology, that provide consistent, high-quality results and see how these multiplex biomarker Luminex® assays are being used to advance research.

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique